

Research Article

The Management of Pregnancies Complicated by Immune Thrombocytopenic Purpura: A Retrospective Analysis of 22 Patients

Adnan Incebiyik^{1*}, Hakan Camuzcuoglu¹, Nese Gul Hilali¹, Aysun Camuzcuoglu¹, Hatice Incebiyik² and Mehmet Vural³

¹Department of Gynecology and Obstetrics, Turkey

²Edassa, Hospital, Internal Medicine clinic, Turkey

³Department of Gynecology and Obstetrics, Turkey

*Corresponding author: Adnan Incebiyik, Department of Obstetrics and Gynecology, Faculty of Medicine, Harran University School of Medicine, Yenisehir Campus, 63300, Turkey, Tel: +904143183027; Fax: +904143183192; Email: dr.aincebiyik@gmail.com

Received: November 18, 2014; Accepted: January 25, 2015; Published: February 25, 2015

Abstract

We aimed to evaluate the clinical characteristics of pregnant women with immune thrombocytopenic purpura (ITP) managed in our clinic. We screened the medical records of 22 pregnant women who delivered in our clinic between 1 January, 2010 and 31 August, 2014. A diagnosis of ITP was made by ruling out other causes of thrombocytopenia. Patients who were diagnosed as having ITP and received therapy before pregnancy were also included in the study. Demographic characteristics and information on whether a patient received treatment for ITP, the maternal platelet count at birth, the administration of a platelet suspension and types of complications at birth were obtained from medical records. ITP was diagnosed during pregnancy follow-up in four of the women and diagnosed before pregnancy in the remaining 18 women who had been managed in the haematology department. The mean maternal platelet count at birth was $47,772.71 \pm 16,523.96/\text{mm}^3$. Seven (31.8%) of the patients received steroid therapy, and two (9.1%) patients received intravenous immunoglobulin (IVIg) therapy. A platelet suspension was given to four of the pregnant women with ITP who had a platelet count $<30,000/\text{mm}^3$ and underwent an emergency delivery. No haemorrhagic complications occurred during post-partum follow-up. ITP is a serious haematological problem that may cause both maternal and neonatal complications. Close monitoring and treatment during pregnancy and at birth can be effective in avoiding haemorrhagic complications.

Keywords: Immune thrombocytopenic purpura; Pregnancy; Steroid; Intravenous immunoglobulin

Introduction

Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder resulting in damaged platelets. The acute form, which is self-limiting and the result of a viral infection, generally affects children. The chronic form generally occurs in the third decade of life and comprises 3% of thrombocytopenia cases observed during pregnancy [1,2]. Antibodies formed in ITP are directed to platelet membrane glycoproteins. In ITP patients, the platelet-antibody complexes are then sequestered and destroyed in the reticuloendothelial system, particularly the spleen [3]. ITP is generally diagnosed before pregnancy. The diagnosis is facilitated by the presence of bleeding and various symptoms, such as bruising, epistaxis, petechiae, a history of menorrhagia. The diagnosis of ITP is done when a platelet count is $<100,000/\text{mm}^3$. These verity is characterized by platelet count $<50,000/\text{mm}^3$. It is recommended to refrain from administering specific treatment in the cases in which the platelet count exceeds the value of $50,000/\text{mm}^3$ [4,5].

The incidence of ITP has been reported to be 1–10/10,000 pregnancies [6]. Research has suggested that ITP is responsible for 3% of thrombocytopenia detected at birth [7]. Pregnant women have a risk of massive bleeding in the post-partum period, depending on the platelet count, with bleeding particularly common at levels below $20,000/\text{mm}^3$. The risk of neonatal thrombocytopenia is 9–15% and

that of intracranial bleeding is 1% due to the trans-placental passage of anti-platelet antibodies in the maternal circulation [8,9]. Thus, pregnant women with ITP need to be monitored closely. Pregnancy does not affect the treatment of ITP. The most commonly used agent is prednisolone, which is intended to maintain the platelet count in the range of $30,000$ to $50,000/\text{mm}^3$ [10-12].

The aim of the present study was to describe the clinical course and treatment protocols of 22 pregnant women with ITP who were managed in our clinic.

Material and Methods

This retrospective study was carried out at the Department of Gynaecology and Obstetrics at our university, and it complied with the Second Declaration of Helsinki (revised in 2008) and was approved by the local ethics committee.

We identified 22 patients by screening an electronic database for patients admitted to the obstetrics clinic with a diagnosis of ITP (ICD code D69.3) and delivery (ICD codes O80, O81, O82, O84) between 1 January, 2010 and 31 August, 2014.

The diagnosis of ITP was based on the presence of thrombocytopenia for at least 6 months, normal bone marrow findings, normal white blood cell and erythrocyte counts and the elimination of other aetiological factors that can cause thrombocytopenia.

Table 1: Demographic characteristics and laboratory data of the 22 pregnant women with immune thrombocytopenic purpura.

	Minimum	Maximum	Mean±SD
Age (years)	18	34	26.27±4.79
Gravidity (n)	1	5	2.18±1.05
Parity (n)	1	6	3.09±1.47
BMI (kg/m ²)	23	34.11	28.50±3.27
Gestational week at delivery	34	41	38.22±1.72
Birth weight (gr)	2600	4250	3209±440.12
Hemoglobin (gr/dl)	9.6	13.5	11.25±1.13
Platelet at delivery (/mm ³)	15000	75000	47772.73±16523.96

Demographic characteristics and information on whether the patient received treatment for ITP, the maternal platelet count at birth, the administration of a platelet suspension and types of complications at birth were obtained from medical records.

Exclusion criteria

Patients with gestational thrombocytopenia, thrombocytopenic purpura, disseminated intravascular coagulation, systemic lupus erythematosus, drug-induced thrombocytopenia, pre-eclampsia, eclampsia and haemolytic uremic syndrome were excluded who could have findings of thrombocytopenia in a complete blood count.

Results

(Table 1) summarises the demographic characteristics and laboratory data of the 22 pregnant women with ITP who were included in the present study. ITP was diagnosed during pregnancy follow-up in four (18.18%) of the women (Table 2) and in the remaining 18 (81.82%) women with a diagnosis of ITP before pregnancy who had been managed in the haematology department. These patients who are diagnosed ITP before pregnancy was not refractory to ITP treatment. The platelet count in the beginning of pregnancy ranged between 34,000/mm³ and 74,000/mm³. Two of the patients with ITP who were diagnosed before pregnancy had previously undergone splenectomy.

During the pregnancy follow-up, intrauterine growth retardation was detected in two patients, and mild pre-eclampsia was detected in another patient. No complications were detected in the remaining 19 patients during pregnancy.

Nine (40.9%) of the pregnant women with ITP did not receive any treatment during pregnancy, and their platelet count at birth was higher than 50,000/mm³. Seven (31.8%) of the patients received steroid therapy, and two (9.1%) received intravenous immunoglobulin (IVI g) therapy. A platelet suspension was given to four of the pregnant women with ITP who had a platelet count <30,000/mm³ and underwent an emergency caesarean section (The indications for

caesarean section were previous caesarean, fetal malpresentation and placenta previa).

Of the patients, 15 (68.2%) gave birth by vaginal delivery, and seven (31.8%) underwent a caesarean section.

Discussion

The platelet count decreases by approximately 10% during pregnancy, especially in the third trimester. This reduction is a benign condition and does not require treatment [13]. It is thought to be caused by haemodilution and increased platelet consumption during pregnancy. The platelet count was reported to be below 150,000/mm³ in 6–15% of all pregnancies, representing asymptomatic thrombocytopenia [14]. In general, a reduced platelet count is detected by chance during routine complete blood counts, and it is the second most common haematological abnormality, with anaemia being the most common [15]. When thrombocytopenia is detected during pregnancy, a meticulous evaluation should be performed to detect maternal and neonatal complications, as well as systemic diseases [8,15].

Gestational thrombocytopenia (70%) is the most common cause of thrombocytopenia diagnosed during pregnancy; followed by hypertensive disorders of gestation (21%) and idiopathic thrombocytopenic purpura (3%). Other less common abnormalities include disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, haemolytic uremic syndrome, systemic lupus erythematosus, congenital thrombocytopenia, hypersplenism and drug-induced thrombocytopenia [14–17].

ITP is an autoimmune disorder characterized by a decreased platelet count due to anti-platelet factors in the structure of immunoglobulin G [1,6]. Antibodies formed in ITP are directed to platelet membrane glycoproteins, and the platelet-antibody complex of the reticuloendothelial system, particularly the spleen, is destroyed. Although ITP can occur at any age, it generally affects women of reproductive age [11]. Both maternal and foetal problems can occur in pregnancies complicated by ITP. Maternal risks include haemorrhages and increased rates of caesarean sections, and foetal risks include intrauterine growth retardation, prematurity, foetal distress, neonatal thrombocytopenia and intracranial bleeding [8,11, 18]. Diagnostic criteria for ITP include the onset of thrombocytopenia before the third trimester, the presence of thrombocytopenia before pregnancy, a platelet count <75,000/mm³ and the persistence of thrombocytopenia after birth [1,15].

ITP is often confused with gestational thrombocytopenia. Gestational thrombocytopenia is the most common cause of thrombocytopenia in pregnancy [14]. Diagnostic criteria for gestational thrombocytopenia include a normal platelet count in the pre-conception and early gestational periods, no history of

Table 2: Characteristics of patients with immune thrombocytopenic purpura cases who diagnosed during pregnancy.

	Gestational age at diagnosis	Platelet count at diagnosis	Platelet count at delivery	Treatment	Type of delivery
Case 1	10 week	55.000/mm ³	62.000/mm ³	None	Vaginal delivery
Case 2	14 week	57.000/mm ³	71.000/mm ³	None	Vaginal delivery
Case 3	19 week	28.000/mm ³	51.000/mm ³	Steroid therapy	Vaginal delivery
Case 4	24 week	49.000/mm ³	58.000/mm ³	None	Caesarean section

spontaneous bleeding, a platelet count $>70,000/\text{mm}^3$ and spontaneous resolution of the platelet count within 2–12 weeks after birth [15].

It is important to distinguish gestational thrombocytopenia from ITP for both the mother and infant. Pregnant women with immune thrombocytopenia have a risk of maternal bleeding, depending on their platelet count, with bleeding particularly common at levels below $20,000/\text{mm}^3$. The risk of neonatal thrombocytopenia is 9–15% and that of intracranial bleeding is 1%. These risks are not observed in gestational thrombocytopenia [8].

The American Society of Hematology and the British Society of Haematology recommend treating pregnant women with severe thrombocytopenia or those with haemorrhages accompanied by mild thrombocytopenia. Treatment is recommended when the platelet count is below $10,000/\text{mm}^3$ at any time during pregnancy and when it is below $30,000/\text{mm}^3$ in the second and third trimesters because of the risk of an emergency delivery. Treatment modalities include steroids, immunoglobulin and splenectomy. Due to the rapid destruction, a platelet transfusion is preferred only before surgery and emergency deliveries to decrease the risk of bleeding [13].

In conclusion, pregnant women with ITP should be managed in collaboration with a haematologist. Methyl prednisolone should be given during pregnancy to improve the platelet count. In cases refractory to steroid therapy, IVI g therapy can be given if the delivery is impending. In urgent cases, a platelet suspension can be lifesaving as an adjunct to other treatment modalities.

References

- Kayal L JS, Singh K.. Idiopathic thrombocytopenic purpura. *Contemp Clin Dent*. 2014; 5: 410-414.
- Loustau V, Debouverie O, Canoui-Poitrine F, Baili L, Khellaf M, Touboul C, et al. Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women. *Br J Haematol*. 2014; 166: 929-935.
- Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. *Curr Opin Hematol*. 2010; 17: 585-589.
- Mahey R, Kaur SD, Chumber S, Kriplani A, Bhatla N. Splenectomy during pregnancy: treatment of refractory immune thrombocytopenic purpura. *BMJ Case Rep*. 2013; 24363245.
- Gresikova M. Learning from errors: when a low platelet count in neonate excludes immune thrombocytopenic purpura in mother. *Bratisl Med J* 2013; 114: 232-236.
- Koyama S, Tomimatsu T, Kanagawa T, Kumasawa K, Tsutsui T, Kimura T. Reliable predictors of neonatal immune thrombocytopenia in pregnant women with idiopathic thrombocytopenic purpura. *Am J Hematol*. 2012; 87(1): 15-21.
- Won YW, Moon W, Yun YS, Oh HS, Choi JH, Lee YY, et al. Clinical aspects of pregnancy and delivery in patients with chronic idiopathic thrombocytopenic purpura (ITP). *Korean J Intern Med*. 2005; 20: 129-134.
- Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. *Semin Thromb Hemost*. 2011; 37: 640-652.
- Patil AS, Dotters-Katz SK, Metjian AD, James AH, Swamy GK. Use of a Thrombopoietin Mimetic for Chronic Immune Thrombocytopenic Purpura in Pregnancy. *Obstet Gynecol*. 2013; 122: 483-485.
- Cho FN. Management of severe immune thrombocytopenic purpura in a pregnant woman with inevitable preterm forceps breech delivery. *Taiwan J Obstet Gynecol*. 2011 ; 50: 227-229.
- Fujita A, Sakai R, Matsuura S, Yamamoto W, Ohshima R, Kuwabara H, et al. A retrospective analysis of obstetric patients with idiopathic thrombocytopenic purpura: a single center study. *Int J Hematol*. 2010; 92: 463-7.
- George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. *Blood*. 1996; 88: 3-40.
- Bockenstedt PL. Thrombocytopenia in Pregnancy. *Hematol Oncol Clin N*. 2011; 25: 293-310.
- Incebiyik A VM, Camuzcuoglu A, Hilali NG, Kurnaz F, Camuzcuoglu H. A successful method for severe gestational thrombocytopenia: A rare case study. *Dicle Med J* 2013; 40: 297-300.
- Boehlen F. Thrombocytopenia during pregnancy. *Hämostaseologie*. 2006; 26: 72-74.
- Wang DP, Liang MY, Wang SM. Clinical analysis of pregnancy complicated with severe thrombocytopenia. *Zhonghua fu chan ke za zhi*. 2010; 45: 401-405.
- Gauer RL, Braun MM. Thrombocytopenia. *Am Fam Physician*. 2012; 85: 612-622.
- Gasim T. Immune thrombocytopenic purpura in pregnancy: a reappraisal of obstetric management and outcome. *J Reprod Med*. 2011; 56: 163-168.